Subscribe For More!

Receive the latest news from MVI Pharma

You have been successfully Subscribed! Ops! Something went wrong, please try again.
Edit Template

Detected Particulate Matter During Visual Inspection? Here’s How to Investigate Particles in Injectable Products

In the sterile injectable manufacturing process, detecting particulate matter during visual inspection can be concerning, as it has direct implications for product quality and patient safety. Whether the particle is known or unknown, each finding demands a systematic investigation to determine its impact and address any potential risks. Here’s a step-by-step guide on how to proceed if particulate matter is detected.

Step 1: Reference the Particle Library

The first step in addressing a detected particle is to consult your facility’s particle library. This resource helps categorize particles by type, size, and common origins within the manufacturing process. By matching the particle to known samples, you can quickly assess if it is one that has been encountered previously or if it is entirely new.

Step 2: Determine if the Particle is Known or Unknown

  • If the Particle is Known:

    • Check whether the detected particle count is within acceptable limits for the batch. These limits may be set by internal production specifications or Acceptable Quality Level (AQL) standards. If the particle count does not exceed these limits, no further action may be required. However, if the limits are exceeded, a root cause investigation is necessary to identify the source and mitigate future risks.

  • If the Particle is Unknown:

    • Unknown particles warrant a more thorough evaluation. Begin by assessing whether the particle is likely sterile, using visual indicators and knowledge of the material type. If it is likely sterile, additional sterility testing may not be required. However, if the particle is unlikely sterile, perform sterility testing to ensure the product meets safety standards. Once identified, characterize the unknown particle and add it to the particle library for future reference.

Step 3: Conduct a Root Cause Investigation

If particle limits are exceeded or if the particle is new and unknown, a root cause investigation must be conducted to identify the underlying issues in the manufacturing or inspection processes. This includes evaluating potential sources of contamination and revisiting cleaning and handling protocols. 

Step 4: Perform a Risk Assessment

Use a risk assessment tool to evaluate the severity, occurrence, and detectability of the detected particle:

  • Severity: Assess the potential impact on patient safety if the particle were to remain in the product.
  • Occurrence: Determine the likelihood of the particle type appearing again in the process.
  • Detectability: Evaluate how easily such particles can be detected during routine visual inspections.

This assessment will help quantify the risk level and guide the response efforts.

Step 5: Complete an Impact Assessment

The impact assessment is essential for understanding the broader implications of the particle contamination. Consider how the batch may be affected, potential risks to patient safety, and any downstream impacts on production. As part of this assessment:

  • Develop a mitigation plan to address and reduce contamination risks in future batches.
  • Cross-reference the mitigation strategies with the risk assessment to identify and close any gaps in the current process.

Step 6: Make Decisions

Once the investigation, risk assessment, and impact assessment are complete, Quality Assurance (QA) should make a final decision regarding the batch:

  • Batch Disposition: Determine whether the batch can be released, reworked, or must be rejected based on the findings.
  • Corrective and Preventive Action (CAPA): If systemic issues are uncovered, QA may implement a CAPA to prevent recurrence. This may involve procedural changes, additional training, or enhanced monitoring.

Conclusion: Detecting particulate matter in injectable products requires a careful, structured response. By referencing the particle library, performing detailed risk and impact assessments, and engaging QA in final disposition decisions, manufacturers can ensure product quality and safeguard patient safety. Following these steps not only helps resolve the immediate issue but also strengthens the overall control process for future batches.

MVI Pharma

MVI Pharma

Achieving Essentially Free

Related Posts

5 1 vote
Article Rating
Subscribe
Notify of
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

Leave a Reply

Editors Pick

  • All Post
  • Blogs

Subscribe For News

Sign up for our newsletter to receive the latest content delivered directly to your inbox regularly.

You have been successfully Subscribed! Ops! Something went wrong, please try again.

Latest Posts

  • All Post
  • Analytics
  • Blogs
  • Polls
  • Regulatory
  • Technology
    •   Back
    • Recalls
    • 483s
    • Trends
    • Discussions
    •   Back
    • MVI
    • SAVI
    • AVI
    • AI
    •   Back
    • USP
    • FDA
    • EMA
    • JP
    • CP

2022 HUSQVARNA FC450 ROCKSTAR EDITION

Trending

Subscribe For More!

Get the latest news from MVI Pharma

You have been successfully Subscribed! Ops! Something went wrong, please try again.

Sign up for our newsletter to receive the latest findings, updates, and exclusive content delivered directly to your inbox regularly. Don’t miss out on valuable information that can keep you up-to-date and engaged with our ongoing mission!

Top News

Sponsored News

Bulk Package

Subscriptions

Customer Support

Worldwide Politics

Services

Sponsored News

Bulk Package

Subscriptions

Customer Support

Worldwide Politics

Company

Sponsored News

Bulk Package

Subscriptions

Customer Support

Worldwide Politics

Subscribe For More!

Get the latest news from MVI Pharma

You have been successfully Subscribed! Oops! Something went wrong, please try again.

Sign up for our newsletter to receive the latest findings, updates, and exclusive content delivered directly to your inbox regularly. Don’t miss out on valuable information that can keep you up-to-date and engaged with our ongoing mission!

© 2024 MVI Pharma